Prochymal®, mesenchymal stem cells for treatment of acute myocardial infarction
Prochymal® is an intravenously administered formulation of mesenchymal stem cells (MSCs). Prochymal® was tested to establish the safety and efficacy in patients following first acute myocardial infarction (MI).
It was found that intravenously administered allogeneic MSCs are safe in patients after acute MI. This trial provides pivotal safety and provisional efficacy data for an allogeneic bone marrow-derived stem cell in post-infarction patients.
Read More
Product Information for
Prochymal®, mesenchymal stem cells for treatment of acute myocardial infarction
Links related to the product - may include a range of information sources (e.g., press releases, websites, patents) related to the specific cell therapy application.
Access to this data is limited to
LifeMap Discovery Registered users onlySign in for full access
Access to this data is limited to
LifeMap Discovery Registered users onlySign in for full access
Access to this data is limited to
LifeMap Discovery Registered users onlySign in for full access